Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
Research published in The Lancet HIV earlier this year, experts estimated that, if purchased at scale, the cost of generic lenacapavir could range from USD 35 to USD 46 per person-year. Falling to USD ...
LONDON, July 14 (Reuters) - ViiV Healthcare, the HIV-focused joint venture majority owned by GSK (GSK.L), opens new tab, said on Monday it has expanded its licensing deal with the Medicines Patent ...
Indian drugmakers Dr Reddy's Laboratories and Hetero Labs said on Wednesday that they will sell generic versions of a new and ...
GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and immune-inflammation diseases like lupus. Specialty Medicines now represents ...
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, and the Medicines Patent Pool, or MPP, have signed a new voluntary licensing ...
The world may look back on 2024 as a pivotal time in the fight against AIDS — the start of a revolution in the global biomedical response to HIV using long-acting antiretroviral medicines. Young women ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback